Sponsors

Genomic test for tumour grade

Ipsogen, a company that markets molecular diagnostics assays for leukaemia, has launched MapQuant DxT Genomic Grade. The new assay is a molecular diagnostic test for breast tumour grade, which is an indicator of tumour proliferation, metastasis risk and response to chemotherapy.

Histological tumour grading is considered to be a decision factor in most national and international guidelines on breast cancer treatment. While it is generally recommended that high-grade breast cancer be treated with chemotherapy because it is chemosensitive, most low-grade breast tumours have a good prognosis and often do not respond to chemotherapy.

www.ipsogen.com

Latest Issues

2nd Global Summit on Pathology

Rome, Italy
10-11 April, 2025

The 10 Year Plan - Clinical Innovations Expo

Jubilee Hotel and Conference Centre, Nottingham, UK
15 May, 2025

Transforming Digital Pathology & AI: The Path Forward

Royal College Of Physicians Of Edinburgh
15 May, 2025

BSMT 40th Anniversary Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025

LabMedUK25

Bridgewater Hall, Manchester
9-11 June, 2025